GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Fang Q., Li G., Liu P., Ding P., Gao Y.
Clinical Trial, published in J Adv Res (2026) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- J Adv Res (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40865632
- PMCID
- PMC13131528
- DOI
- 10.1016/j.jare.2025.08.046
- Citations
- 4
Abstract (original English)
Background Musculoskeletal diseases (MSDs) are prevalent health problems that have a chronic course and are closely related to metabolic disorders. Several incretins, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), which are secreted by enteroendocrine cells in response to food intake. In animal experiments, more and more evidence showed that there's a potential connection between GLP-1/GIP and musculoskeletal system cells (such as mesenchymal stem cells, osteoblasts and osteoclasts). As the GLP-1/GIP analogs have obtained global application as slimming magic bullet, it is of interest to further explore whether they are also magic bullet for MSDs apart from merely focusing on its weight-losing effect. Aim of review To help figure out whether GLP-1/GIP is beneficial for musculoskeletal system, this review summarizes the effects of GLP-1 and GIP on musculoskeletal cells and their probable mechanisms. Current results concerning the effects of GLP-1 and GIP in rodent experiments and clinical studies related to the musculoskeletal system are also summarized. Future research should prioritize confirming experimental results through clinical trials, address previous research gaps, and focus on the long-term impact of GLP-1 and GIP. Key scientific concepts of review GLP-1 and GIP may exert protective effect on musculoskeletal cells thro
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.